Corbus Pharmaceuticals Holdings, Inc. (LON:0SZI)
London · Delayed Price · Currency is GBP · Price in USD 7.35
-0.09 (-1.21%)
Feb 12, 2026, 4:54 PM GMT
Corbus Pharmaceuticals Holdings Employees
Corbus Pharmaceuticals Holdings had 28 employees as of December 31, 2024. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-1.79M GBP
Market Cap
106.50M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 28 | 9 | 47.37% |
| Dec 31, 2023 | 19 | -14 | -42.42% |
| Dec 31, 2022 | 33 | -8 | -19.51% |
| Dec 31, 2021 | 41 | -35 | -46.05% |
| Dec 31, 2020 | 76 | -65 | -46.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| EKF Diagnostics Holdings | 297 |
| Diaceutics | 213 |
| 4basebio | 110 |
| Shield Therapeutics | 63 |
Corbus Pharmaceuticals Holdings News
- 2 months ago - Cormorant Asset Management, LP Reduces Stake in Corbus Pharmaceuticals Holdings Inc - GuruFocus
- 2 months ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript - Seeking Alpha
- 2 months ago - Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data - Slideshow - Seeking Alpha
- 2 months ago - Corbus Pharmaceuticals (CRBP) Reports Phase 1 Study Results for Obesity Drug - GuruFocus
- 2 months ago - CRBP: Corbus Pharmaceuticals' Promising Phase I Study Sparks Interest - GuruFocus
- 2 months ago - Corbus Reports Positive Phase 1a Results Of CRB-913 In Obesity, Stock Surges - Update - Nasdaq
- 2 months ago - Corbus Pharmaceuticals (CRBP) Advances Obesity Treatment with CRB-913 Trials - GuruFocus
- 2 months ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire